Home » Posts tagged with » Eli Lilly and Company
Lilly begins phase 1 coronavirus antibody trial with LY-CoV555

Lilly begins phase 1 coronavirus antibody trial with LY-CoV555

Coronavirus antibody trial : US pharma giant Eli Lilly and Company (Lilly) said that patients have been dosed in a phase 1 clinical trial with the investigational antibody LY-CoV555 for the treatment of COVID-19. LY-CoV555 is the first antibody candidate to emerge from Lilly’s collaboration with AbCellera Biologics, which was announced in March 2020, with […]

Selpercatinib FDA approval : Lilly’s therapy approved for treatment of lung and thyroid cancers with RET alteration

Selpercatinib FDA approval : The US Food and Drug Administration (FDA) has approved Eli Lilly and Company’s Retevmo (selpercatinib) capsules for the treatment of three types of tumors – non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers. The approvals are for the drug to be used in patients whose tumors […]

Continue reading …
Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers

Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Retevmo (selpercatinib, 40mg and 80mg capsules) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). Retevmo has also been approved by the FDA for the treatment […]

Continue reading …
Lilly bags Trulicity FDA approval for reducing CV risk in type 2 diabetes patients

Trulicity FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Trulicity (dulaglutide) to reduce major cardiovascular events (MACE) in type 2 diabetes patients having established cardiovascular (CV) disease or multiple cardiovascular risk factors. The latest FDA approval Trulicity means that the drug the first […]

Continue reading …
Lilly to build $470m pharma manufacturing plant in North Carolina

US pharma giant Eli Lilly and Company (Lilly) will build a new pharma manufacturing plant in North Carolina with an investment of more than $470 million for producing injectable products and delivery devices. The new Lilly pharma manufacturing facility will be built in Research Triangle Park, and will generate over 460 new jobs in Durham. […]

Continue reading …
Lilly to acquire US dermatology drug company Dermira for $1.1bn

Lilly acquisition of Dermira : US pharma giant Eli Lilly and Company (Lilly) has agreed to acquire California-based dermatology drug company Dermira for about $1.1 billion in an all-cash deal as per the latest pharma acquisition news. Dermira, which is being acquired for $18.75 per share, has been engaged in developing dermatology products for the […]

Continue reading …
Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC

Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) in patients who are treatment-naïve. The US pharma company is aiming to enroll 400 patients in the late-stage clinical trial. The patients will be grouped randomly to be subjected to […]

Continue reading …
Lilly bags Reyvow FDA approval for acute treatment of migraine

Reyvow FDA approval : Eli Lilly and Company (Lilly) has bagged approval from the US Food and Drug Administration (FDA) for Reyvow (lasmiditan) for the acute treatment of migraine, irrespective of aura (a sensory phenomenon or visual disturbance), in adults. The oral treatment, which has been designed to bind to 5-HT1F receptors with high affinity, […]

Continue reading …
Lilly bags Taltz FDA approval for ankylosing spondylitis

Taltz FDA approval : The US Food and Drug Administration (FDA) has approved US pharma giant Eli Lilly and Company’s Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults having active ankylosing spondylitis (AS). Also known as radiographic axial spondyloarthritis (r-axSpA), ankylosing spondylitis is a type of spondyloarthritis that affects the pelvic joints and […]

Continue reading …
MONARCH 2 clinical trial results : Verzenio, fulvestrant combo improves overall survival in metastatic breast cancer

MONARCH 2 clinical trial results : Eli Lilly and Company (Lilly) said that Verzenio (abemaciclib) in combination with fulvestrant delivered a statistically significant improvement in overall survival in the phase 3 MONARCH 2 clinical trial held for a type of metastatic breast cancer. The US pharma giant said that the MONARCH 2 clinical trial results […]

Continue reading …
Page 1 of 212